Skip to main content
. Author manuscript; available in PMC: 2016 Jul 27.
Published in final edited form as: ACS Infect Dis. 2015 Jul 27;1(8):340–349. doi: 10.1021/acsinfecdis.5b00070

Figure 6.

Figure 6

Broad-spectrum antiviral analysis for compound NSC 12155. (A) Cytotoxicity of NSC 12155. Human A549 cells were incubated with various concentrations of the compound and then assayed for viability at 42 h post-incubation. (B–F) Inhibition of viral replication of DENV-2 (B), SLEV (C), JEV (D), and negative control viruses VSV (E) and WEEV (F) by NSC 12155. A549 cells were infected with viruses at a multiplicity of infection of 0.1, in the presence or absence of compounds. At 42 h post-infection, viral titers in culture fluids were quantified by plaque assays on Vero cells. Each reaction was carried out in triplicate, and the standard deviation is plotted.